Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056934 | 0.94 | SCD (0.56) | SCDMAPTROCK2LMNAMEN1 | |
| SCHEMBL3055325 | 0.82 | MAPT (0.57) | SCDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL3063830 | 0.81 | MAPT (0.52) | SCDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL2314157 | 0.78 | SCD (0.71) | SCDMAPTLMNAMEN1ALDH1A1 | |
| SCHEMBL3651494 | 0.78 | RNASEH1 (0.48) | MAPTLMNAKMT2ARNASEH1PDE5A | |
| SCHEMBL7383453 | 0.77 | MAPT (0.72) | SCDMAPTROCK2LMNAMEN1 | |
| SCHEMBL2311672 | 0.76 | SCD (0.62) | SCDMAPTROCK2LMNAMEN1 | |
| SCHEMBL403310 | 0.76 | PDE5A (0.62) | MAPTLMNAALDH1A1KMT2ARNASEH1 | |
| SCHEMBL2313190 | 0.75 | SCD (1.00) | SCDMAPT | |
| SCHEMBL2316986 | 0.73 | SCD (0.86) | SCDMAPTLMNAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267752-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-10-21 | — | — | US | claimed |
| WO-2010045374-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-04-22 | — | — | WO | claimed |
| US-20100267752-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267752-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267752-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| WO-2010045374-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267752-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | SCD 1/4885MAPT 4221/4885ROCK2 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.